Tanning Peptides: Melanotan I, Melanotan II & the Real Risks
Safety note. Melanotan II is not approved by the FDA for any use and its safety has not been established. Published case reports link it to melanoma, ischemic priapism, rhabdomyolysis, and renal infarction. This page explains the pharmacology and the evidence so you can evaluate the claims made about it. It is not a protocol and not medical advice.
Tanning peptides are synthetic copies of alpha-melanocyte-stimulating hormone, the signal your body uses to tell pigment cells to darken. They work, and that part is not in dispute. The dispute is over what else they do. One of them, Melanotan I, earned FDA approval in 2019 for a rare photosensitivity disease and is administered as a clinician-placed implant. The other, Melanotan II, is the one people actually buy, is approved nowhere, and carries a case-report record that dermatologists find alarming for a cosmetic product. This guide covers the mechanism, what the evidence supports, and where the risk actually sits.
What Is a Tanning Peptide?
Your skin color at any moment is the output of a hormone signal. When UV radiation damages skin cells, they produce alpha-melanocyte-stimulating hormone (alpha-MSH), which binds the melanocortin 1 receptor (MC1R) on melanocytes. Those cells respond by manufacturing eumelanin, the brown-black pigment, and shipping it to surrounding keratinocytes, where it sits above the nucleus like a parasol. That is a tan: cellular damage triggering a defensive pigment response.
Tanning peptides short-circuit the trigger. They are alpha-MSH analogs, so they bind MC1R directly and drive melanin production without waiting for UV damage to start the cascade. Native alpha-MSH is useless as a drug because it degrades in minutes; the synthetic analogs were engineered for stability, which is why they last long enough to do anything at all.
There are three peptides in this family worth knowing. Melanotan I (afamelanotide) is a 13-amino-acid linear peptide, relatively MC1R-selective, FDA approved for a rare disease. Melanotan II is a 7-amino-acid cyclic peptide, non-selective across melanocortin receptors, approved nowhere, and the one sold online. Bremelanotide (PT-141) is a metabolite of Melanotan II that was developed away from tanning entirely and approved for hypoactive sexual desire disorder, which is a useful clue about what MT-II does besides pigment. For the broader category, see what peptides are and how they differ from other compounds.
How Melanocortin Agonists Work
The melanocortin system has five receptors, and where they sit in the body determines what happens when a peptide binds them. This is the single most important fact for understanding why Melanotan II produces the side effect profile it does.
| Receptor | Where It Lives | What Activation Does |
|---|---|---|
| MC1R | Melanocytes, immune cells | Eumelanin synthesis, the tanning effect |
| MC2R | Adrenal cortex | Cortisol release (ACTH receptor; MSH analogs bind it poorly) |
| MC3R | Hypothalamus, gut | Energy balance, inflammation, nausea |
| MC4R | Central nervous system | Appetite suppression, erectile response |
| MC5R | Sebaceous glands, exocrine tissue | Sebum production |
Melanotan I was designed to favor MC1R. Melanotan II was designed for potency, not selectivity. It is a cyclic lactam-bridged molecule that binds MC1R, MC3R, MC4R, and MC5R. So a person injecting Melanotan II to get a tan is also agonizing the appetite and erection receptor in their brain and the nausea circuitry in their hypothalamus. The nausea, the appetite drop, and the spontaneous erections are not idiosyncratic reactions. They are the drug working exactly as its structure predicts.
This is also why MC4R agonism became its own drug class. Bremelanotide was spun out of the Melanotan II program precisely because researchers noticed the erectile effect and developed it as the intended effect instead of the side effect.
Melanotan I (Afamelanotide): The One the FDA Approved
Afamelanotide is the only melanocortin tanning agonist with an FDA approval, and the terms of that approval are worth reading closely, because they are routinely misrepresented by vendors selling the other thing.
On October 8, 2019, the FDA approved Scenesse (afamelanotide) as a 16 mg subcutaneous implant to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria. The EMA had approved it in 2014. EPP is a rare inherited disorder in which protoporphyrin accumulates in the skin and reacts to light, causing severe burning pain on sun exposure. Increasing melanin gives these patients a tolerable amount of time outdoors. That is the indication: pain-free light exposure in a photosensitivity disease.
Three details matter. First, it is an implant, inserted above the anterior supra-iliac crest by a trained clinician every two months, not a vial you reconstitute. Second, it is prescribed and monitored, including dermatologic surveillance. Third, cosmetic tanning is not an approved indication and was never the trial endpoint. An approval for a rare photosensitivity disorder is not evidence that MSH analogs are safe as a beach accessory, and it says nothing at all about Melanotan II, which is a different molecule with a different receptor profile.
Melanotan II: What People Actually Buy
Melanotan II is not approved by the FDA for any use and its safety has not been established. The FDA has issued warning letters to distributors. It reaches buyers through the same channel as most research peptides: lyophilized powder in a vial, labeled for research use only and not for human consumption, shipped by vendors who are legally insulated by that sentence and by nothing else.
The practical consequence is that nobody, including the buyer, knows what is in the vial. There is no USP monograph being followed, no release testing you can audit, no chain of custody. Independent testing of the research-peptide market repeatedly turns up products that are underdosed, overdosed, degraded, or contain something other than what the label claims. For a compound where dose scales directly with both pigmentation and priapism risk, not knowing the dose is not a minor problem. Our guide to peptide storage and handling covers why lyophilized peptides degrade and what that means for anything shipped without cold chain.
Regulators elsewhere have been blunter than the FDA. Australia's Therapeutic Goods Administration has publicly urged consumers to avoid Melanotan II, and UK and EU authorities have taken similar positions. It is worth asking why a compound with a genuinely effective cosmetic result has attracted consumer warnings rather than a development program.
What the Evidence Actually Shows
Be precise about the state of the evidence, because both sides of this argument overstate it.
What is well established: melanocortin agonists increase eumelanin and darken skin. This is settled pharmacology, demonstrated in the afamelanotide trials and visible in every Melanotan II user. Nobody disputes that tanning peptides tan.
What is not established: that Melanotan II causes melanoma. The evidence consists of published case reports, covering melanoma diagnosed after use, new nevus formation, rapid darkening and growth of existing nevi, and dysplastic nevus eruption. Case reports are the weakest tier of clinical evidence. They cannot control for confounders, and the obvious confounder here is enormous: people who inject a tanning drug are, as a group, people who pursue sun exposure. Anyone claiming Melanotan II is a proven carcinogen is going beyond the data.
Why the uncertainty does not resolve in the drug's favor: the absence of proof here is not reassuring, because there is no system that could produce proof. Melanotan II has no manufacturer, no trials, no post-market surveillance, and no adverse event reporting pathway. A harm signal that would surface within months for an approved drug can persist indefinitely for this one, because nobody is collecting the data. No evidence of harm and no evidence collected look identical from the outside, and only one of them is comforting.
The concern that does not depend on causation: the peptide changes moles. It darkens them, and case reports describe them enlarging and multiplying. Early melanoma detection rests almost entirely on noticing that a mole changed. A drug that makes every mole on your body change at once degrades the primary screening signal, whether or not it ever causes a single cancer. That is the mechanistic argument behind the Skin Cancer Foundation's warning, and it stands independent of the case-report debate.
Side Effects and Case Reports
The common effects are predictable from the receptor map above and are reported by most users:
- Nausea — frequent enough that dosing before sleep is the standard workaround. MC3R and MC4R mediated.
- Facial flushing — vasodilation shortly after injection.
- Appetite suppression — MC4R agonism, the same axis targeted by the approved obesity drug setmelanotide.
- Spontaneous erections — MC4R again, the effect that became bremelanotide.
- Darkening of moles and freckles — often does not fully reverse.
- Blotchy, uneven pigmentation — melanin deposition is not uniform, particularly over scars.
The serious effects come from the case-report literature, and the list is unusual for a cosmetic product: ischemic priapism (a urological emergency that can cause permanent erectile damage if untreated), rhabdomyolysis (skeletal muscle breakdown that can precipitate kidney failure), renal infarction, and posterior reversible encephalopathy syndrome. These are individually rare. They are also individually severe, and the same caveat cuts both ways: without surveillance, nobody knows the true incidence.
For how peptide side effects are evaluated more generally, see our peptide side effects guide.
The Photoprotection Misconception
The most common claim made for tanning peptides is that a peptide-induced tan is safer than a UV tan, because you get the color without the DNA damage. The first half is true. The second half is where it collapses.
Melanin does absorb UV, and increased eumelanin does provide some baseline photoprotection. But the magnitude is modest, comparable to a low single-digit SPF, which is not a meaningful defense and not remotely a substitute for sunscreen. A tan has never been good sun protection; that is why dermatologists have spent forty years saying so.
The behavioral problem is worse than the pharmacological one. Most Melanotan II protocols circulating online explicitly pair the peptide with UV exposure, sunbeds or sun, on the theory that UV activates or deepens the response. So the typical user is not substituting peptide for UV. They are adding peptide to UV, while feeling protected, while their moles change appearance. Every element of that combination points the wrong direction.
Legality and Sourcing
Melanotan II sits where most research peptides sit. It is not a controlled substance, so possessing it is not a criminal offense in the US. It is an unapproved new drug, so marketing or selling it for human use is illegal, and the FDA has issued warning letters to distributors doing exactly that. The research-use-only label is what vendors use to stay on the legal side of that line. It does not make the compound safer, tested, or legal to inject. It makes the buyer responsible.
Afamelanotide runs on the opposite model: prescription-only, dispensed through certified clinicians for EPP, implanted rather than injected. There is no cosmetic pathway to it. Anyone advertising pharmaceutical-grade Melanotan I for tanning is not selling Scenesse.
For the wider regulatory picture, see are peptides legal. Note also that the FDA's July 2026 Pharmacy Compounding Advisory Committee agenda, covering BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, and Epitalon, does not include either Melanotan. See our PCAC hearing coverage for what that process involves and the FDA peptide category framework for how compounds get sorted.
Who Uses These, and the Honest Read
Tanning peptides attract two groups with almost nothing in common. EPP patients receive afamelanotide as genuine medicine for a painful disease with few alternatives; the risk-benefit math there is straightforward and the FDA agreed with it. Cosmetic users buy Melanotan II because it delivers a deep tan quickly, including for fair-skinned people who burn rather than tan, which is the exact MC1R-variant population that struggles to get color from UV at all.
The uncomfortable part of the second case is that it is not irrational. Fair-skinned users who tan chemically instead of by burning are, in principle, avoiding the mechanism that actually causes melanoma. If Melanotan II were manufactured to standard, dosed by a clinician, and paired with dermatologic monitoring and strict UV avoidance, the argument would be worth having on the merits.
None of those conditions hold. The product is unregulated and of unknown content, the dose is self-titrated to effect, the protocols pair it with UV rather than replacing UV, and the drug degrades the mole-watching that would catch a problem early. The pharmacology is not the objection. The delivery system around it is.
Key Takeaways
- Tanning peptides are alpha-MSH analogs that drive melanin production through melanocortin receptors. They work.
- Melanotan I (afamelanotide) is FDA approved as a clinician-placed implant for erythropoietic protoporphyria, not for cosmetic tanning.
- Melanotan II is approved nowhere, sold as a research chemical, and non-selective across MC1R to MC5R, which is why nausea, appetite loss, and erections come with the tan.
- The melanoma link rests on case reports and is not proven. The screening problem, that the drug changes every mole you have, does not require proof to matter.
- A peptide tan is not sunscreen. Real-world protocols add UV rather than replacing it.
- Serious case reports include priapism, rhabdomyolysis, renal infarction, and PRES. Incidence is unknown because nobody is counting.
Related reading: Melanotan 1 vs Melanotan 2, PT-141 (bremelanotide), GHK-Cu for skin, GHK-Cu serum, peptide therapy overview, how to inject peptides, peptide half-life chart, and the Huberman peptide list.
Frequently Asked Questions About Tanning Peptides
A tanning peptide is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), the hormone your body uses to trigger pigment production. These peptides bind melanocortin receptors, mainly MC1R on melanocytes, and push those cells to make more eumelanin, the dark pigment responsible for tanning. The three compounds people mean by the term are Melanotan I (afamelanotide), Melanotan II, and to a lesser extent bremelanotide (PT-141), which shares the same chemical lineage but is used for sexual dysfunction rather than pigmentation.
No. Melanotan II is not approved by the FDA for any use, and its safety has not been established. The FDA has issued warning letters to distributors selling it. It is sold online as a research chemical outside any regulatory framework, which means no manufacturing standards, no dosing guidance, no purity guarantees, and no adverse event monitoring. Regulators outside the US have gone further: Australia's TGA has publicly urged consumers to avoid it.
One is, for a narrow purpose. Afamelanotide (brand name Scenesse), which is Melanotan I, was approved by the FDA on October 8, 2019 as a 16 mg subcutaneous implant to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria (EPP), a rare genetic photosensitivity disorder. The EMA approved it in 2014. It is not approved, prescribed, or studied as a cosmetic tanning product, and it is administered as an implant by a trained clinician every two months rather than self-injected.
Causation has not been established, and it likely cannot be from the evidence that exists. What does exist is a body of published case reports documenting melanoma diagnosed after Melanotan II use, along with new mole formation, rapid darkening and enlargement of existing moles, and dysplastic nevus eruption. Case reports cannot prove cause and effect, and they cannot rule out that these users also had heavy UV exposure or pre-existing risk. The more defensible concern is mechanistic and practical: the peptide changes how moles look, and mole appearance is the primary screening signal dermatologists rely on to catch melanoma early. The Skin Cancer Foundation has issued a warning about the compound on that basis.
The common, well-documented ones are nausea (frequent enough that users often dose at night to sleep through it), facial flushing, appetite suppression, spontaneous erections in men, darkening of existing moles and freckles, and uneven or blotchy pigmentation. The serious effects come from published case reports: ischemic priapism (a urological emergency), rhabdomyolysis, renal infarction, and posterior reversible encephalopathy syndrome. Because Melanotan II is a non-selective melanocortin agonist, it hits MC1R through MC5R rather than only the pigment receptor, which is the structural reason its effects extend well beyond skin.
Melanotan I (afamelanotide) is a linear 13-amino-acid peptide that is relatively selective for MC1R, the pigment receptor. Melanotan II is a shorter cyclic 7-amino-acid peptide that binds MC1R, MC3R, MC4R, and MC5R non-selectively. That selectivity difference explains almost everything downstream: MT-II tans faster and at lower doses, but MC3R and MC4R activity drives the nausea and appetite suppression while MC4R activity drives the erectile effects. MT-I has a cleaner receptor profile and an approved medical form; MT-II has neither.
No, and this is the most consequential misconception about them. Melanocortin agonists increase melanin, and melanin does provide some baseline photoprotection, but the effect is modest, roughly equivalent to a low single-digit SPF, not a substitute for sunscreen. Worse, most tanning-peptide protocols circulating online pair the peptide with deliberate UV exposure to activate the tan, so real-world use tends to increase total UV dose rather than reduce it. A darker appearance with unchanged or higher UV exposure is the opposite of photoprotection.
Melanotan II occupies the same gray zone as most research peptides: it is not a controlled substance, so possession is not itself a crime, but it is an unapproved drug, so selling it for human use is illegal and the FDA has acted against distributors. Vendors route around this by labeling it for research use only, not for human consumption, a disclaimer that shifts liability to the buyer without changing what the product is. Afamelanotide is a prescription drug available only through certified clinicians for EPP, not obtainable for cosmetic use.
We are describing what circulates, not recommending it. Online protocols typically run a loading phase of 250-500 mcg daily until the desired shade is reached, then a maintenance phase of 500-1000 mcg once or twice weekly, reconstituted from lyophilized powder with bacteriostatic water. There is no established therapeutic dose because there are no human dosing trials for cosmetic use, so these numbers come from user forums rather than evidence. Doses are self-titrated against skin darkening, which means users escalate until they see an effect, and the melanocortin side effects scale with dose.
Reported anecdotally at roughly 1-3 months of gradual fade after stopping, tracking the normal turnover of pigmented keratinocytes as they migrate up and shed. This is longer than a UV tan because pigment is deposited more deeply and continuously during dosing. Moles and freckles darkened during use often do not return to baseline, which is the durable cosmetic change users most frequently report regretting.